- Home
- ECO vs CDNA Comparison
ECO vs CDNA Comparison
Compare ECO & CDNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ECO | CDNA |
|---|---|---|
| Founded | 2018 | 1998 |
| Country | Greece | United States |
| Employees | N/A | N/A |
| Industry | | Medical Specialities |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.0B |
| IPO Year | N/A | 2014 |
Fundamental Metrics
Financial Performance| Metric | ECO | CDNA |
|---|---|---|
| Price | $32.94 | $19.93 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 7 |
| Target Price | ★ $37.00 | $26.67 |
| AVG Volume (30 Days) | 249.4K | ★ 695.3K |
| Earning Date | 02-18-2026 | 02-25-2026 |
| Dividend Yield | ★ 6.43% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.38 | 1.22 |
| Revenue | $349,886,578.00 | ★ $357,998,000.00 |
| Revenue This Year | N/A | $14.11 |
| Revenue Next Year | $5.10 | $11.75 |
| P/E Ratio | ★ $13.85 | $16.30 |
| Revenue Growth | N/A | ★ 14.46 |
| 52 Week Low | $17.91 | $10.96 |
| 52 Week High | $39.77 | $25.95 |
Technical Indicators
Market Signals| Indicator | ECO | CDNA |
|---|---|---|
| Relative Strength Index (RSI) | 41.79 | 60.33 |
| Support Level | $31.75 | $18.75 |
| Resistance Level | $33.89 | $20.61 |
| Average True Range (ATR) | 0.78 | 0.73 |
| MACD | -0.22 | -0.17 |
| Stochastic Oscillator | 26.52 | 52.07 |
Price Performance
Historical ComparisonAbout ECO Okeanis Eco Tankers Corp.
Okeanis Eco Tankers Corp owns and operates tanker vessels in Greece. The business of the company is to own, charter out, and operate tanker vessels. The company owns, through its vessel-owning subsidiaries, a fleet of around seven tanker vessels and has around eight tanker vessels on order. The sailing fleet consists of around six modern Suezmax tankers and eight VLCC tankers.
About CDNA CareDx Inc.
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically the company generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.